# NGM Biopharmaceuticals Inc. (NGM)

Source: https://www.quantisnow.com/company/NGM
Generated: 2026-11-11T17:20:56.027Z

- Ticker: NGM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: ngmbio.com

## About

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

## Latest NGM news and filings

- 2025-07-09 16:00 UTC [Leadership Update] [Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer](https://www.quantisnow.com/insight/xaira-therapeutics-announces-the-appointment-of-jeff-jonker-as-president-6115269)
- 2024-04-15 11:57 UTC [SEC Form 15-12G filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-ngm-biopharmaceuticals-inc-5409477)
- 2024-04-09 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ngm-biopharmaceuticals-inc-5398879)
- 2024-04-09 00:05 UTC [SEC Form 4] [Tcg Opportunity Iii Gp, Llc returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/tcg-opportunity-iii-gp-llc-returned-21743413-shares-to-the-5398690)
- 2024-04-09 00:04 UTC [SEC Form 4] [Column Group Gp, Lp returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/column-group-gp-lp-returned-21743413-shares-to-the-company-5398689)
- 2024-04-09 00:03 UTC [SEC Form 4] [Column Group L P returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/column-group-l-p-returned-21743413-shares-to-the-company-5398688)
- 2024-04-09 00:02 UTC [SEC Form 4] [Goeddel David V returned 22,008,593 shares to the company and acquired 1,000 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/goeddel-david-v-returned-22008593-shares-to-the-company-and-5398687)
- 2024-04-08 20:18 UTC [SEC Form 4] [Pierce Valerie L closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/pierce-valerie-l-closing-all-direct-ownership-in-the-company-5398030)
- 2024-04-08 20:16 UTC [SEC Form 4] [Rieflin William Jl closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/rieflin-william-jl-closing-all-direct-ownership-in-the-company-5398014)
- 2024-04-08 20:14 UTC [SEC Form 4] [Viret Jean-Frederic closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/viret-jean-frederic-closing-all-direct-ownership-in-the-company-sec-5397986)
- 2024-04-08 20:14 UTC [SEC Form 4] [Woodhouse David J closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/woodhouse-david-j-closing-all-direct-ownership-in-the-company-5397983)
- 2024-04-08 20:14 UTC [SEC Form 4] [Perlich Irene closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/perlich-irene-closing-all-direct-ownership-in-the-company-sec-5397982)
- 2024-04-08 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Ho Carole](https://www.quantisnow.com/insight/sec-form-4-filed-by-ho-carole-5397959)
- 2024-04-08 20:12 UTC [SEC Form 4] [SEC Form 4 filed by Guyer Shelly D](https://www.quantisnow.com/insight/sec-form-4-filed-by-guyer-shelly-d-5397945)
- 2024-04-08 20:12 UTC [SEC Form 4] [Hooper Suzanne Sawochka closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/hooper-suzanne-sawochka-closing-all-direct-ownership-in-the-company-5397941)
- 2024-04-08 20:09 UTC [SEC Form 4] [SEC Form 4 filed by Perlmutter Roger M](https://www.quantisnow.com/insight/sec-form-4-filed-by-perlmutter-roger-m-5397898)
- 2024-04-08 20:08 UTC [SEC Form 4] [Lieu Hsiao D closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/lieu-hsiao-d-closing-all-direct-ownership-in-the-company-5397882)
- 2024-04-05 15:22 UTC [SEC Form 25-NSE filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-ngm-biopharmaceuticals-inc-5394559)
- 2024-04-05 14:55 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-ngm-biopharmaceuticals-inc-amendment-5394500)
- 2024-04-05 14:54 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ngm-biopharmaceuticals-inc-5394496)
- 2024-04-05 14:53 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ngm-biopharmaceuticals-inc-5394493)
- 2024-04-05 14:53 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ngm-biopharmaceuticals-inc-5394491)
- 2024-04-05 14:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ngm-biopharmaceuticals-inc-5394488)
- 2024-04-05 14:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ngm-biopharmaceuticals-inc-5394485)
- 2024-04-05 14:40 UTC [SEC Form POS AM filed by NGM Biopharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-ngm-biopharmaceuticals-inc-5394462)
- 2024-04-05 14:10 UTC [SEC Form 8-K] [NGM Biopharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant](https://www.quantisnow.com/insight/ngm-biopharmaceuticals-inc-filed-sec-form-8-k-completion-of-acquisition-5394406)
- 2024-04-05 13:48 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-ngm-biopharmaceuticals-inc-amendment-5394353)
- 2024-04-05 13:27 UTC [SEC Form SC 13E3/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13e3a-filed-by-ngm-biopharmaceuticals-inc-amendment-5394307)
- 2024-04-05 13:24 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-ngm-biopharmaceuticals-inc-amendment-5394295)
- 2024-04-05 13:19 UTC [Public Offering] [NGM Bio Announces Closing of Tender Offer](https://www.quantisnow.com/insight/ngm-bio-announces-closing-of-tender-offer-5394276)
- 2024-04-04 20:42 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-ngm-biopharmaceuticals-inc-amendment-5393200)
- 2024-03-29 20:56 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-ngm-biopharmaceuticals-inc-amendment-5378131)
- 2024-03-22 21:30 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-ngm-biopharmaceuticals-inc-amendment-5364554)
- 2024-03-22 21:21 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-ngm-biopharmaceuticals-inc-amendment-5364512)
- 2024-03-22 21:19 UTC [SEC Form SC 13E3/A filed by NGM Biopharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13e3a-filed-by-ngm-biopharmaceuticals-inc-amendment-5364505)
- 2024-03-19 21:32 UTC [Market Chatter] [NGM Bio To Present Two Posters Highlighting Clinical Data From Ongoing Phase 1/2 Clinical Trial Of NGM707, A Dual ILT2/ILT4 Antagonist Antibody Product Candidate, At AACR 2024 Annual Meeting](https://www.quantisnow.com/insight/ngm-bio-to-present-two-posters-highlighting-clinical-data-from-5355718)
- 2024-03-19 21:30 UTC [NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting](https://www.quantisnow.com/insight/ngm-bio-to-present-two-posters-highlighting-clinical-data-from-5355703)
- 2024-03-12 11:29 UTC [Analyst Downgrade] [NGM Biopharmaceuticals downgraded by Raymond James](https://www.quantisnow.com/insight/ngm-biopharmaceuticals-downgraded-by-raymond-james-5336060)
- 2024-03-12 09:24 UTC [Market Chatter] [Raymond James Downgrades NGM Biopharmaceuticals to Market Perform](https://www.quantisnow.com/insight/raymond-james-downgrades-ngm-biopharmaceuticals-to-market-perform-5335729)
- 2024-03-11 20:20 UTC [Market Insight] [NGM Biopharmaceuticals Q4 EPS $(0.33) Beats $(0.39) Estimate, Sales $165.00K Miss $560.00K Estimate](https://www.quantisnow.com/insight/ngm-biopharmaceuticals-q4-eps-033-beats-039-estimate-sales-16500k-5334299)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NGM
- Earnings history: https://www.quantisnow.com/earnings/NGM
- Dividend history: https://www.quantisnow.com/dividends/NGM
- Insider transactions: https://www.quantisnow.com/insiders/NGM
- Options chain: https://www.quantisnow.com/options/NGM
- SEC 8-K filings only: https://www.quantisnow.com/company/NGM/8-k
- RSS and alerts for NGM: https://www.quantisnow.com/docs/rss-feeds.md